

1 Association of comorbidities with COVID-19 infection rate and severity: nationwide cohort
2 study with propensity score matching

3

4 Jiyong Kim¹, Seong Hun Park² and Jong Moon Kim^{3,4}

5 *¹Department of physical medicine and rehabilitation, Inje University Ilsanpaik Hospital,*
6 *Goyang, Republic of Korea*

7 *²Medical statistics company WIO*

8 *³Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University,*
9 *Seongnam, Republic of Korea*

10 *⁴Department of Medical Informatics Big Data Center, CHA Bundang Medical Center, CHA*
11 *University, Seongnam, Republic of Korea*

12

13 Corresponding author: Jong Moon Kim

14 Address: Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA
15 University, 59 Yatap-ro, Bundang-gu, Seongnam, Gyeonggi-do, Republic of Korea, 13496

16 Tel: 82-31-780-5456

17 Fax: 82-31-780-3449

18 E-mail: khan1013@chamc.co.kr

19

20 Word count: 1992

21

22 **ABSTRACT**

23 **OBJECTIVE:** To describe the association of comorbidities with coronavirus infection-19
24 (COVID-19) infection rates and severity of infection through Korean nationwide medical
25 system.

26 **DESIGN:** Nationwide population-based retrospective cohort study.

27 **SETTING:** Korean national health insurance claims database between January 1, 2020, and
28 May 30, 2020.

29 **PARTICIPANTS:** Patients with positive COVID-19 test and 12 folded controls matched by age,
30 sex and region.

31 **MAIN OUTCOMES MEASURES:** Outcomes were confirmation of the comorbidities affecting
32 the infection rate and the severity of COVID-19. Patients and outcomes were propensity
33 score matching of factors which may affect COVID-19 infection rate and severity was
34 performed. COVID-19 infections were confirmed through laboratory testing. Severe infection
35 was defined as those who underwent tracheostomy, continuous renal replacement therapy,
36 intensive care unit admission, ventilator use, cardiopulmonary resuscitation, or died.

37 **RESULTS:** A total of 8070 individuals with positive covid-19 test and 12015 controls were
38 identified. In people aged 60 or older, in those insured with Medicaid, and in the disabled, the
39 proportion corresponding to the severe group of patients showed a tendency to increase. The
40 infection rate of COVID-19 was highest in pulmonary disease (adjusted odds ratio 1.88, 95%
41 confidence interval 1.70 to 2.03), and hyperlipidemia (0.73, 0.67 to 0.80) had a lower

42 infection rate. Disease severity was highest in kidney disease (5.59, 2.48 to 12.63), and lower
43 in hyperlipidemia (0.78, 0.60 to 1.00).

44 **CONCLUSIONS:** There is less bias as the government pays for all tests and treatments related
45 to COVID-19 included in the data used in this study. Using propensity matching to reduce
46 statistical bias, we found that most comorbidities increased the infection rate and severity of
47 COVID-19, whereas hyperlipidemia reduced the rate and severity of infection. These results
48 can be utilized to effectively manage COVID-19 infections.

49 **KEY WORDS:** COVID-19; Comorbidity; Severity of illness index; Hyperlipidemias

50 INTRODUCTION

51 Vaccines against coronavirus infection-19 (COVID-19) have been developed, but the
52 number of infections and deaths of COVID-19 is still increasing worldwide.¹ COVID-19
53 infection can cause asymptomatic or flu-like symptoms, but some patients are admitted to
54 hospital for conservative treatment, some require ventilator treatment, and in severe cases
55 some patients may die.^{2,3} As the number of people infected with COVID-19 increases, it is
56 important to identify those who are vulnerable to severe COVID-19 infection in order to
57 effectively manage health care facilities.^{4,5}

58 Since the COVID-19 outbreak, many studies have been conducted on demographic factors
59 and comorbidity of infected patients. Most studies have reported similar overall results, but
60 there are differences in detailed results, and some contradictory results have been reported.⁶⁻⁹
61 This difference in results may be due to the diversity of subjects and medical systems, as
62 studies have been conducted in various countries around the world, but it may also be
63 because factors other than COVID-19 infection have not been sufficiently considered.

64 In this study, the effect of patient comorbidities on the infection rate and severity of
65 COVID-19 was investigated with reduced bias through propensity matching for various
66 variables. We also analyzed demographic factors for patients infected with COVID-19.

67

68 METHODS

69 Study design and participants

70 We conducted a large-scale cohort study using a South Korean national health insurance
71 claims database.¹⁰ In South Korea, all citizens are registered under the Korean National

72 Health Insurance Service (KNHIS) and this database was used for this study. The KNHIS
73 utilizes a nationwide large scale database system, including information of the diagnostic
74 codes of the International Classification of Diseases (ICD-10), the names of procedures
75 performed, prescription drugs, hospital information, direct medical costs of inpatient and
76 outpatient treatments, as well as information on medical insurance premiums. Since all
77 Koreans are given unique identification numbers at birth and these numbers are used in
78 KNHIS, the health records of patients are not duplicated or omitted.^{11 12} This study used the
79 database “NHIS-2020-1-328” provided by the KNHIS. From January 1 to May 30, 2020,
80 subjects with disease codes B342, B972, U071, U072, MT043, 3/02 were used to identify
81 confirmed COVID-19 patients. A control group equivalent to 15 times the number of
82 confirmed COVID-19 cases with adjusted sex, age, and region was also provided.

83

84 **Study population**

85 Laboratory confirmation of COVID-19 infection was defined as a positive result according to
86 World Health Organization guidelines.¹³ We combined the claims-based data from the
87 KNHIS between 1 January 2015 and 30 May 2020 and extracted information on the age, sex
88 and region of residence from the insurance eligibility data. Certain underlying diseases with a
89 high risk of serious illness due to the virus that causes COVID-19, published by the Centers
90 for Disease Control and Prevention and previous studies,^{6-9, 14} were selected; among them,
91 only those with more than 500 people infected with COVID-19 were selected. The history of
92 underlying diseases (Pulmonary disease, Cardiovascular disease, Kidney disease,
93 Hepatobiliary disease, Hyperlipidemia, Gastrointestinal disease, Diabetes mellitus,

94 Hypertension, Psychotic disorder, Dementia, Stroke, Neurogenic disorder, Autoimmune
95 disease, Cancer) was confirmed by the assignment of at least two claims within 1 year using
96 the appropriate ICD-10 code (Supplement 1). The Charlson Comorbidity Index (CCI) score
97 was calculated from the ICD-10 codes by using previously reported methods.¹⁵

98

99 **Outcomes**

100 To determine the severity of the disease according to the demographic factors of COVID-19
101 infected patients, the severity scale was divided into four grades: mild, moderate, severe, and
102 death. In South Korea, patients with asymptomatic or mild symptoms are discharged when a
103 negative COVID-19 test is confirmed two weeks after hospitalization, which corresponds to
104 the period of self-isolation. When we checked the hospitalization period of COVID-19
105 infected patients, the hospitalization period peaked on the 16th day and decreased thereafter.
106 Based on this result, the hospitalization period of 16 days or less was defined as a mild grade
107 corresponding to asymptomatic or mild symptoms (Supplement 2-1, 2). Severe grade was
108 defined as tracheostomy, continuous renal replacement therapy, intensive care unit (ICU)
109 admission, ventilator use, and cardiopulmonary resuscitation. Moderate grade was defined as
110 a case where the hospitalization period was longer than 16 days and the treatment
111 corresponding to the severe grade was not performed.

112 The primary outcome was a comparison of COVID-19 infected and control groups and
113 severity grade according to demographic factors, comorbidity, and complications. The
114 secondary result was performed through propensity score (PS) matching for the comparison
115 target. We identified the degree of infection rate and severity (severe + death / mild +

116 moderate) of COVID-19 according to the comorbidity condition.

117

118 **Statistical analysis**

119 We performed PS matching to balance the baseline characteristics of each comorbidity
120 (existence-nonexistence) and to adjust for potential confounders. The PS is estimated using a
121 logistic regression model, calculating the predicted probability of covariates 1) age, 2) CCI (0,
122 1, or ≥ 2) was matched for continuous variables, and 3) sex, 4) medication and 5) other
123 comorbidities were matched with binary variables. We assessed each PS matching of the
124 comorbidity existence in a 1:1 ratio using the 'greedy nearest neighbor' algorithm and a scale
125 with a caliper of 0.25. Data after PS matching were analyzed by calculating adjusted odds
126 ratios with 95% confidence intervals (CIs) for infection rate and severity (severe + death /
127 mild + moderate) of COVID-19.

128

129 **RESULTS**

130 **Clinical characteristics of the study population**

131 A total of 8070 people had positive results on the COVID-19 test. We identified 121,050
132 uninfected people as control subjects (Figure). The demographic characteristics of the entire
133 cohort are displayed in Table 1. The severity grade of COVID-19 infected persons was mild
134 in 2419 (29.98%), moderate in 5160 (63.94%), severe in 254 (3.15%), and death in 237
135 (2.94%). Among the total infected people, 3236 (40.10%) were male, and the most common
136 ages were people in their 50s (19.42%) and 60s (14.86%). In terms of the medical insurance
137 grade which indicates socioeconomic status, Medicaid had a high rate of severe or death, but

138 the other grades did not have any obvious tendencies. By region, 5264 (65.23%) of infected
 139 people occurred in Daegu, because many infections occurred in Daegu in February and
 140 March. People with disabilities had more severe infections and had a much higher mortality
 141 rate.

Table 1 | Baseline characteristics

Variables	Severity*				COVID-19	Control§
	Mild	Moderate	Severe	Death	Total†	
Sex						
Male	894 (27.63)	2073 (64.06)	135 (4.17)	134 (4.14)	3236 (40.10)	48540
Female	1525 (31.55)	3087 (63.86)	119 (2.46)	103 (2.13)	4834 (59.90)	72510
Age						
0~9	32 (39.51)	45 (55.56)	4 (4.94)	0 (0.00)	81 (1.00)	1215
10~19	77 (27.90)	195 (70.65)	4 (1.45)	0 (0.00)	276 (3.42)	4140
20~29	697 (33.88)	1342 (65.24)	18 (0.88)	0 (0.00)	2057 (25.49)	30855
30~39	273 (32.81)	541 (65.02)	17 (2.04)	1 (0.12)	832 (10.31)	12480
40~49	358 (34.56)	655 (63.22)	20 (1.93)	3 (0.29)	1036 (12.84)	15540
50~59	504 (32.16)	1006 (64.20)	43 (2.74)	14 (0.89)	1567 (19.42)	23505
60~69	322 (26.86)	776 (64.72)	66 (5.50)	35 (2.92)	1199 (14.86)	17985

70~79	122 (19.77)	389 (63.05)	40 (6.48)	66 (10.70)	617 (7.65)	9255
80~	34 (8.40)	211 (52.10)	42 (10.37)	118 (29.14)	405 (5.02)	6075
Medical insurance‡						
Medicaid	186 (27.56)	416 (61.63)	31 (4.59)	42 (6.22)	675 (8.36)	4424 (3.65)
Grade 1	604 (32.95)	1146 (62.52)	44 (2.40)	39 (2.13)	1833 (22.71)	26258 (21.69)
Grade 2	462 (30.84)	971 (64.82)	36 (2.40)	29 (1.94)	1498 (18.56)	24270 (20.05)
Grade 3	484 (29.02)	1081 (64.81)	58 (3.48)	45 (2.70)	1668 (20.67)	27521 (22.74)
Grade 4	637 (28.07)	1475 (65.01)	79 (3.48)	78 (3.44)	2269 (28.12)	37241 (30.76)
Region						
Seoul	102 (18.75)	433 (79.60)	4 (0.74)	5 (0.92)	544 (6.74)	8160
Dae-gu	1629 (30.95)	3352 (63.68)	133 (2.53)	150 (2.85)	5264 (65.23)	7896
Gyeonggi-do	156 (34.59)	265 (58.76)	15 (3.33)	15 (3.33)	451 (5.59)	6765
Gyeongsangbuk-do	266 (27.82)	573 (59.94)	66 (6.90)	51 (5.33)	956 (11.85)	14340
Others	266 (31.11)	537 (62.81)	36 (4.21)	16 (1.87)	855 (10.59)	12825

Disability grade						
Mild	65 (20.44)	192 (60.38)	28 (8.81)	33 (10.38)	318 (3.94)	4367 (3.61)
Severe	83 (27.57)	166 (55.15)	18 (5.98)	34 (11.30)	301 (3.73)	2275 (1.88)
Total	2419 (29.98)	5160 (63.94)	254 (3.15)	237 (2.94)	8070 (100)	121050 (100)

*: The number in parentheses means the ratio of each row to the COVID-19 Total

†: The number in parentheses means the ratio of the total number of COVID-19 confirmed cases, 8070 people

§: The number in parentheses means the ratio of 12,1050 total control subjects

‡: Subjects to some specific groups, such as soldiers, are not included.

142 Those infected with COVID-19 had histories of gastrointestinal disease, pulmonary disease,
 143 hyperlipidemia, and hypertension in that order, and the mortality rate was high in cases of
 144 kidney disease, dementia, and immunocompromised disease (Table 2-1). After COVID-19
 145 infection was confirmed, gastrointestinal disease, pulmonary disease, and hyperlipidemia
 146 were the most common in that order. The mortality rate was high in cases of kidney disease,
 147 dementia, and cardiovascular disease (Table 2-2).

Table 2-1 | Baseline characteristics of comorbidity

Variables	Severity*				COVID-19 Total†	Control§
	Mild	Moderate	Severe	Death		
Pulmonary disease	687 (27.06)	1566 (61.68)	123 (4.84)	163 (6.42)	2539 (31.46)	11834 (9.78)
Cardiovascular disease	141 (21.08)	380 (56.80)	40 (5.98)	108 (16.14)	669 (8.29)	6754 (5.58)

Kidney disease	15	37	9	25	86	1018
	(17.44)	(43.02)	(10.47)	(29.07)	(1.07)	(0.84)
Hepatobiliary disease	311	756	56	89	1212	10770
	(25.66)	(62.38)	(4.62)	(7.34)	(15.02)	(8.90)
Hyperlipidemia	482	1142	97	120	1841	24620
	(26.18)	(62.03)	(5.27)	(6.52)	(22.81)	(20.34)
Gastrointestinal disease	1600	3293	181	182	5256	58798
	(30.44)	(62.65)	(3.44)	(3.46)	(65.13)	(48.57)
Diabetes mellitus	254	712	69	133	1168	13062
	(21.75)	(60.96)	(5.91)	(11.39)	(14.47)	(10.79)
Hypertension	363	995	95	170	1623	22904
	(22.37)	(61.31)	(5.85)	(10.47)	(20.11)	(18.92)
Psychotic disorder	262	666	67	100	1095	10796
	(23.93)	(60.82)	(6.12)	(9.13)	(13.57)	(8.92)
Dementia	19	104	25	64	212	1336
	(8.96)	(49.06)	(11.79)	(30.19)	(2.63)	(1.90)
Stroke	16	57	7	11	91	689
	(17.58)	(62.64)	(7.69)	(12.09)	(1.13)	(0.57)
Neurogenic disorder	28	72	4	15	119	1037
	(23.53)	(60.50)	(3.36)	(12.61)	(1.47)	(0.86)
Autoimmune disease	53	113	5	9	180	2423
	(29.44)	(62.78)	(2.78)	(5.00)	(2.23)	(2.00)
Cancer	55	158	19	37	269	2423
	(20.45)	(58.74)	(7.06)	(13.75)	(3.33)	(2.00)

*: The number in parentheses means the ratio of each row to the COVID-19 Total

†: The number in parentheses means the ratio of the total number of COVID-19 confirmed cases, 8070 people

§: The number in parentheses means the ratio of 12,1050 total control subjects

Table 2-2 | Baseline characteristics of complication

Variables	Severity*				COVID-19 Total†	Control§
	Mild	Moderate	Severe	Death		
Pulmonary disease	542 (22.60)	1580 (65.89)	180 (7.51)	96 (4.00)	2398 (29.71)	2027 (1.67)
Cardiovascular disease	161 (20.77)	475 (61.29)	85 (10.97)	54 (6.97)	775 (9.60)	1223 (1.01)
Kidney disease	12 (11.01)	50 (45.87)	22 (20.18)	25 (22.94)	109 (1.35)	226 (0.19)
Hepatobiliary disease	321 (25.72)	789 (63.22)	107 (8.57)	31 (2.48)	1248 (15.46)	4359 (3.60)
Gastrointestinal disease	824 (28.30)	1906 (65.45)	129 (4.43)	53 (1.82)	2912 (36.08)	20477 (16.92)
Stroke	6 (13.33)	27 (60.00)	10 (22.22)	2 (4.44)	45 (0.56)	298 (0.25)
Neurogenic disorder	21 (28.77)	40 (54.79)	12 (16.44)	3 (4.11)	73 (0.90)	169 (0.14)
Sepsis	16 (10.46)	71 (46.41)	38 (24.84)	28 (18.30)	153 (1.90)	22 (0.02)

*: The number in parentheses means the ratio of each row to the COVID-19 Total
†: The number in parentheses means the ratio of the total number of COVID-19 confirmed cases, 8070 people
§: The number in parentheses means the ratio of 12,1050 total control subjects

149

150 **COVID-19 test result positivity risks and disease severity according to comorbidity**

151 To identify differences according to comorbidity, predispositions were matched between

152 COVID-19 infected, control group, and COVID-19 infected individuals in each cohort. No

153 significant imbalances in the demographics and clinical characteristics were observed when
154 assessed using standardized mean difference (SMD) within groups of PS-matched cohorts.
155 (The SMD of binary type variables < 0.1) PS-matched odds ratios were checked for age, sex,
156 CCI, comorbidity, and medication. When compared with the control group in the COVID-19
157 infected group, it was confirmed that COVID-19 infection was more prone for most of the
158 history presented in Table 3, except for the history of hyperlipidemia (adjusted odds ratio,
159 0.73 [95% CI, 0.67-0.80]), autoimmune disease (0.73, 0.60 to 0.89) and cancer (0.73, 0.62 to
160 0.86). In COVID-19 infected subjects, the severity grade was high for pulmonary disease
161 (1.72, 1.35 to 2.19), cardiovascular disease (1.54, 1.17 to 2.04), kidney disease (5.59, 2.48 to
162 12.63), diabetes mellitus (1.43, 1.09 to 1.87), hypertension (1.63, 1.23 to 2.15), psychotic
163 disorder (1.29, 1.01 to 6.52), dementia (2.92, 1.91 to 4.47), and cancer (1.84, 1.15 to 2.94),
164 and lower with hyperlipidemia (0.70, 0.55 to 0.90) (Table 4).

Table 3 | Propensity score-matched baseline characteristics and COVID-19 infection test positivity according to comorbidity

Variables	Group		Adjusted odds ratio (95% CI)
	COVID-19	Control	
Pulmonary disease*	2880	22900	1.88 (1.70, 2.03)
Cardiovascular disease*	1245	13733	1.20 (1.07, 1.35)
Kidney disease	171	2037	1.01 (0.74, 1.39)
Hepatobiliary disease*	1959	20505	1.31 (1.19, 1.44)
Hyperlipidemia†	2375	25663	0.73 (0.67, 0.80)
Gastrointestinal disease*	3164	43370	1.74 (1.62, 1.88)
Diabetes mellitus*	1544	16468	1.28 (1.16, 1.43)
Hypertension	1483	16473	1.04 (0.93, 1.15)
Psychotic disorder	2122	21458	1.06 (0.97, 1.16)

Dementia*	365	2753	1.75 (1.40, 2.20)
Stroke*	194	1662	1.67 (1.23, 2.27)
Neurologic disease	223	2089	1.16 (0.88, 1.53)
Autoimmune disease†	421	4785	0.73 (0.60, 0.89)
Cancer†	629	6459	0.73 (0.62, 0.86)

*: Comorbidity to be more susceptible to COVID-19
 †: Comorbidity to be less infected with COVID-19

165

Table 4 | Propensity score-matched baseline characteristics and clinical outcomes of COVID-19 among mild/moderate group versus severe/death groups according to comorbidity in patients with confirmed laboratory COVID-19 infection

Variables	Severity		Adjusted odds ratio (95% CI)
	Mild/Moderate	Severe/Death	
Pulmonary disease*	3031	307	1.72 (1.35, 2.19)
Cardiovascular disease*	1078	252	1.54 (1.17, 2.04)
Kidney disease*	129	43	5.59 (2.48, 12.63)
Hepatobiliary disease	1899	253	1.01 (0.78, 1.31)
Hyperlipidemia†	2204	270	0.78 (0.60, 1.00)
Gastrointestinal disease	3060	206	1.00 (0.75, 1.33)
Diabetes mellitus*	1465	259	1.43 (1.09, 1.87)
Hypertension*	1262	248	2.92 (1.91, 4.47)
Psychotic disorder*	1846	288	1.29 (1.01, 6.52)
Dementia*	305	137	2.92 (1.91, 4.47)
Stroke	188	50	1.36 (0.72, 2.54)
Neurologic disease	198	40	0.88 (0.45, 1.75)
Autoimmune disease	338	20	2.25 (0.92, 6.52)
Cancer*	448	88	1.84 (1.15, 2.94)

*: Comorbidity of increasing severity of COVID-19

†: Comorbidity of decreasing severity of COVID-19

166

167 **DISCUSSION**

168 This study is a retrospective cohort study conducted in South Korea from January to May
169 2020 with most of the confirmed COVID-19 infected patients enrolled in medical insurance.

170 Previous studies on the demographic factors of people infected with COVID-19 showed that
171 men, older men, and lower income levels are factors that are more likely to be associated with
172 people infected with COVID-19 and with a higher severity grade.^{16 17} In this study, more
173 women were infected with COVID-19, but the severity grade was higher in men and was
174 directly proportional to age, especially in men over 70 years. In terms of socioeconomic
175 status, the severity grade was higher in the case of Medicaid with the lowest income level, but
176 there was no trend in the rest of the groups. This differs from studies conducted in other
177 countries, possibly because South Korea pays the entire medical cost for COVID-19
178 infections. In people with disabilities, the incidence was slightly higher than in the control
179 group, but the severity grade was much higher than other people when infected.

180 According to studies of the COVID-19 virus, the COVID-19 virus binds to the angiotensin-
181 converting enzyme 2 (ACE2) receptor through the viral structural spike protein at the
182 beginning of infection.¹⁸ ACE2 is expressed to varying degrees in almost all human organs.
183 ACE2 is highly expressed in cardiomyocytes, proximal tubule cells of the kidney, and
184 bladder urinary tract cells, and is abundantly expressed in intestinal cells of the small
185 intestine, especially in the ileum.¹⁸⁻²¹ Therefore, most critically ill patients with COVID-19
186 infection suffer multiple organ injuries including acute lung injury, acute kidney injury,

187 cardiac injury, hepatobiliary disease, and pneumothorax.²²

188 Therefore, to analyze the effect of each comorbidity on the severity grade when infected with

189 COVID-19, it is necessary to consider other comorbidities. In this study, the influence on

190 each comorbidity was confirmed by selecting as many comorbidities as possible for

191 statistically meaningful matching of COVID-19 confirmed patients. Most results were similar

192 to those of previously published studies; however, some results were conflicting.

193 In this study, people with hyperlipidemia had a low infection rate of COVID-19 and a low

194 severity grade. Previous studies reported that hyperlipidemia should be managed to prevent

195 COVID-19 infection because high cholesterol induces inflammation and increases ACE2

196 availability.²³⁻²⁵ On the other hand, there have been studies showing that patients with

197 hypolipidemia are susceptible to infection, and in some studies, when the lipid level is low,

198 cases of COVID-19 infection are higher than that of the control group, and there are studies

199 showing that the severity level is higher.²⁶⁻³³ This may be similar to the 'obesity paradox' that

200 describes the fact that it is more advantageous if there is mild obesity in the process of

201 improvement after stroke.^{34, 35} Mild obesity can withstand the systemic catabolic imbalance

202 with impaired metabolic efficiency and degradation of body tissues that occurs after stroke.

203 Hyperlipidemia may also play a role in minimizing the severity of COVID-19 infection.

204 Our study has several limitations. We defined diseases based on ICD codes in insurance

205 claims data. There may be additional unmeasured confounders influencing our results,

206 including genetic polymorphisms, smoking, body mass index and the exposure of the virus.

207 In this study as well, the infection rate of COVID-19 may have been influenced by the degree

208 of exposure to the COVID-19 virus as an important factor in addition to the comorbidity

209 factors.

210 However, in this study, the influence of COVID-19 itself could be confirmed because the bias
211 was less than that of previous studies. First, South Korea has a population of more than 95%
212 of one race, hence there is minimal racial bias compared to previous studies. Second, because
213 the government funds treatment for COVID-19 infection in South Korea, and the medical
214 facilities for COVID-19 treatment are ubiquitous, there is minimal economic bias. Third,
215 because the PS matching was performed on sex, age, CCI, and comorbidity, selection bias
216 was also minimized. Therefore, more accurate information on the infection rate and disease
217 severity of COVID-19 according to comorbidities could be provided in this study.

218 In conclusion, certain comorbidities, known as risk factors in previous studies, increase the
219 infection rate and severity of COVID-19; hyperlipidemia decreases the infection rate and
220 severity. These results can be utilized to effectively manage COVID-19 infections.

221 Author Contributions: JMK and JK both had full access to all the data in the study and take
222 responsibility for the integrity of the data and the accuracy of the data analysis.

223 Concept and design: JMK and JK

224 Acquisition, analysis, or interpretation of data: PSH and JMK

225 Drafting of the manuscript: JMK and JK

226 Statistical analysis: PSH and JK

227 Obtained funding: JMK

228

229 Funding/Support: This research was supported by the Bio & Medical Technology
230 Development Program of the National Research Foundation (NRF) funded by the Korean
231 government (MSIT) (No.2016M3A9E8941108).

232 Role of the Funder/Sponsor: National Research Foundation had no role in the design and
233 conduct of the study. The authors are responsible for the design and conduct of the study;
234 collection, management, analysis, and interpretation of the data; preparation, review, or
235 approval of the manuscript; and the decision to submit the manuscript for publication.

236

237 Competing interests: All authors have completed the ICMJE uniform disclosure form at
238 <http://www.icmje.org/disclosure-of-interest/> and declare: no support from any organization
239 for the submitted work; no financial relationships with any organizations that might have an
240 interest in the submitted work in the previous three years; and no other relationships or
241 activities that could appear to have influenced the submitted work.

242 Ethical approval: This research protocol was approved by the institutional review board
243 (2020-06-052)

244 Data sharing: The dataset for the national health insurance sharing data is available on request
245 (<https://nhiss.nhis.or.kr/bd/ab/bdabd003cv.do>). Informed consent was not obtained, but the
246 presented data are anonymised and the risk of identification is low.

247 Transparency: The lead author (JMK) affirms that the manuscript is an honest, accurate, and
248 transparent account of the study being reported; that no important aspects of the study have
249 been omitted; and that any discrepancies with the study as planned (and, if relevant,
250 registered) have been explained.

251 **Key points**

252 **WHAT IS ALREADY KNOWN ON THIS TOPIC**

253 In previous studies, studies on comorbidity and the infection rate and severity of COVID-19
254 were conducted, but conflicting results were also obtained.

255

256 **WHAT THIS STUDY ADDS**

257 The relationship between comorbidity and COVID-19 was confirmed by minimizing the bias
258 by using propensity matching and the characteristic that the Korean government pays all
259 costs for COVID-19. While most comorbidities increased the infection rate and severity of
260 COVID-19, hyperlipidemia reduced the infection rate and severity.

261 **REFERENCE**

- 262 1. Organization WH. Coronavirus disease (COVID-19). 2020
- 263 2. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000
264 patients with coronavirus disease 2019 in New York: retrospective case series. *Bmj*
265 2020;m1996. doi: 10.1136/bmj.m1996
- 266 3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,
267 and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City
268 Area. *Jama* 2020;323(20):2052. doi: 10.1001/jama.2020.6775
- 269 4. Moghadas SM, Shoukat A, Fitzpatrick MC, et al. Projecting hospital utilization during the
270 COVID-19 outbreaks in the United States. *Proceedings of the National Academy of Sciences*
271 2020;117(16):9122-26. doi: 10.1073/pnas.2004064117
- 272 5. Murray CJ. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days
273 and deaths by US state in the next 4 months: Cold Spring Harbor Laboratory, 2020.
- 274 6. Fang X, Li S, Yu H, et al. Epidemiological, comorbidity factors with severity and
275 prognosis of COVID-19: a systematic review and meta-analysis. *Aging* 2020;12(13):12493-
276 503. doi: 10.18632/aging.103579 [published Online First: 2020/07/13]
- 277 7. Kim DW, Byeon KH, Kim J, et al. The Correlation of Comorbidities on the Mortality in
278 Patients with COVID-19: an Observational Study Based on the Korean National Health
279 Insurance Big Data. *Journal of Korean Medical Science* 2020;35(26) doi:
280 10.3346/jkms.2020.35.e243
- 281 8. Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19:
282 evidence from meta-analysis. *Aging* 2020;12(7):6049-57. doi: 10.18632/aging.103000

- 283 9. Gold MS, Sehayek D, Gabrielli S, et al. COVID-19 and comorbidities: a systematic review
284 and meta-analysis. *Postgraduate Medicine* 2020;132(8):749-55. doi:
285 10.1080/00325481.2020.1786964
- 286 10. Service NHI. National Health Insurance Program. *National Health Insurance Service*
287 2021:<https://www.nhis.or.kr/static/html/wbd/g/a/wbdga0401.html>.
- 288 11. An C, Lim H, Kim D-W, et al. Machine learning prediction for mortality of patients
289 diagnosed with COVID-19: a nationwide Korean cohort study. *Scientific reports* 2020;10(1)
290 doi: 10.1038/s41598-020-75767-2
- 291 12. Kim JM, Park JH, Kim HS, et al. Epidemiology and diagnostic process of amyotrophic
292 lateral sclerosis as distinct from myelopathy: 5-year cohort study of whole-population in
293 South Korea. *Amyotrophic lateral sclerosis & frontotemporal degeneration* 2018;19(7-
294 8):547-54. doi: 10.1080/21678421.2018.1491600 [published Online First: 2018/11/14]
- 295 13. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–Angiotensin–Aldosterone System
296 Inhibitors and Risk of Covid-19. *New England Journal of Medicine* 2020;382(25):2441-48.
297 doi: 10.1056/nejmoa2008975
- 298 14. Prevention CfDCa. People with Certain Medical Conditions. *Centers for Disease Control*
299 *and Prevention* 2020: [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)
300 [precautions/people-with-medical-conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html).
- 301 15. Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated
302 with proton pump inhibitors: a nationwide cohort study with propensity score matching. *Gut*
303 2021;70(1):76-84. doi: 10.1136/gutjnl-2020-322248
- 304 16. Drefahl S, Wallace M, Mussino E, et al. A population-based cohort study of socio-

- 305 demographic risk factors for COVID-19 deaths in Sweden. *Nature Communications*
306 2020;11(1) doi: 10.1038/s41467-020-18926-3
- 307 17. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis,
308 and Treatment of Coronavirus Disease 2019 (COVID-19). *Jama* 2020;324(8):782. doi:
309 10.1001/jama.2020.12839
- 310 18. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on
311 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*
312 2020;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052
- 313 19. Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in
314 COVID-19. *Critical Care* 2020;24(1) doi: 10.1186/s13054-020-03120-0
- 315 20. Zhang H, Li H-B, Lyu J-R, et al. Specific ACE2 expression in small intestinal enterocytes
316 may cause gastrointestinal symptoms and injury after 2019-nCoV infection. *International*
317 *Journal of Infectious Diseases* 2020;96:19-24. doi: 10.1016/j.ijid.2020.04.027
- 318 21. Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2
319 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV
320 infection. *Frontiers of Medicine* 2020;14(2):185-92. doi: 10.1007/s11684-020-0754-0
- 321 22. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with
322 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational
323 study. *The Lancet Respiratory Medicine* 2020;8(5):475-81. doi: 10.1016/s2213-
324 2600(20)30079-5
- 325 23. Radenkovic D, Chawla S, Pirro M, et al. Cholesterol in Relation to COVID-19: Should
326 We Care about It? *Journal of Clinical Medicine* 2020;9(6):1909. doi: 10.3390/jcm9061909


- 327 24. Wang H, Yuan Z, Pavel MA, et al. The role of high cholesterol in age-related COVID19
328 lethality: Cold Spring Harbor Laboratory, 2020.
- 329 25. Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and
330 during its pandemic: An expert panel position statement from HEART UK. *Atherosclerosis*
331 2020;313:126-36. doi: 10.1016/j.atherosclerosis.2020.09.008
- 332 26. Ahn C, Hwang Y, Park SK. Predictors of all-cause mortality among 514,866 participants
333 from the Korean National Health Screening Cohort. *PloS one* 2017;12(9):e0185458. doi:
334 10.1371/journal.pone.0185458
- 335 27. Park CH, Kang EW, Park JT, et al. Association of serum lipid levels over time with
336 survival in incident peritoneal dialysis patients. *Journal of Clinical Lipidology*
337 2017;11(4):945-54.e3. doi: 10.1016/j.jacl.2017.06.004
- 338 28. Zuliani G, Volpato S, Dugo M, et al. Combining LDL-C and HDL-C to predict survival in
339 late life: The InChianti study. *PloS one* 2017;12(9):e0185307. doi:
340 10.1371/journal.pone.0185307
- 341 29. Wang MC, Hu HY, Lin IF, et al. Plasma lipid concentrations and survival in geriatric
342 population: A retrospective cohort study. *Medicine (Baltimore)* 2019;98(49):e18154. doi:
343 10.1097/md.00000000000018154 [published Online First: 2019/12/06]
- 344 30. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. *Bmj*
345 2020:m1182. doi: 10.1136/bmj.m1182
- 346 31. Wei X, Zeng W, Su J, et al. Hypolipidemia is associated with the severity of COVID-19.
347 *Journal of Clinical Lipidology* 2020;14(3):297-304. doi: 10.1016/j.jacl.2020.04.008
- 348 32. Hu X, Chen D, Wu L, et al. Low Serum Cholesterol Level Among Patients with COVID-

- 349 19 Infection in Wenzhou, China. *China (February 21, 2020)* 2020
- 350 33. Wang G, Zhang Q, Zhao X, et al. Low high-density lipoprotein level is correlated with the
351 severity of COVID-19 patients: an observational study. *Lipids in Health and Disease*
352 2020;19(1) doi: 10.1186/s12944-020-01382-9
- 353 34. Scherbakov N, Dirnagl U, Doehner W. Body Weight After Stroke. *Stroke; a journal of*
354 *cerebral circulation* 2011;42(12):3646-50. doi: 10.1161/strokeaha.111.619163
- 355 35. Andersen KK, Olsen TS. The Obesity Paradox in Stroke: Lower Mortality and Lower
356 Risk of Readmission for Recurrent Stroke in Obese Stroke Patients. *International Journal of*
357 *Stroke* 2013;10(1):99-104. doi: 10.1111/ijvs.12016


358 **Figure | Disposition of patients in the Korean nationwide cohort**

Population

Identification



Propensity Score matching by comorbidity



Outcomes

